Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05704062 · ClinicalTrials.gov registry record
Quantitative MRI Assessment of Breast Cancer Therapy Response
A clinical trial of Breast Cancer, sponsored by Corewell Health East.
- Recruiting
- Registry status
- 135
- Enrollment target
- 4
- Study locations
NCT05704062 is a study of Breast Cancer that is actively recruiting participants, run by Corewell Health East. The registered enrollment target is 135 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05704062, a study of Breast Cancer, is actively recruiting participants, sponsored by Corewell Health East.
- RECRUITING
- Registry status
- 135 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this observational study is to investigate and validate multi-parametric magnetic resonance imaging (MRI) modalities for assessment of breast cancer response to neoadjuvant chemotherapy in a multi-site and multi-MRI scanner platform setting. This study is conducted at Oregon Health \& Science University (OHSU), University of Washington (UW), and University of Iowa (UI) using Siemens, Philips, and General Electric MRI scanners, respectively. MRI is a type of scan that uses a very strong magnet and no radiation to take very detailed pictures of parts of the body. MRI is often used as standard of care to take pictures of breast tumor(s) before and after chemotherapy treatment in order to measure the tumor size changes in response to treatment, and in order to plan for surgery. MRI is used because the images it takes are very clear and the borders of the tumor can be measured very accurately. However the tumor size alone is often not a good early indicator of whether or not the tumor responds to treatment. Tumor size change usually happens late during the period of treatment, and tumor size measured with MRI after treatment can overestimate or underestimate the residual cancer. This makes it difficult to do the right surgical planning. In addition to measuring tumor size, the MRI scans in this research study will also measure changes in tumor blood vessels and the number of cancer cells per unit of tumor volume. The purpose of this study is to see whether MRI measurements of these functional tumor properties provide better early prediction and evaluation of breast cancer response to neoadjuvant chemotherapy than tumor size measurement. This is an observational study because the MRI procedures are not expected to have an effect on health outcomes. Eligible participants on this study are receiving standard of care neoadjuvant treatment for their cancer.
Conditions Studied
Interventions
- PROCEDURE Diffusion Weighted Imaging
- PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Study Locations (4)
Iowa
- University of Iowa - Iowa City
Michigan
- Corewell Health William Beaumont University Hospital - Royal Oak
Oregon
- OHSU Knight Cancer Institute - Portland
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2010-03-18 |
| Est. Completion | 2027-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05704062
The ClinicalTrials.gov registry entry for NCT05704062 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Corewell Health East, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Diffusion Weighted Imaging is the first listed.
NCT05704062 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Iowa, Michigan, Oregon.
Frequently Asked Questions
What is clinical trial NCT05704062 about?
NCT05704062 is a clinical study titled "Quantitative MRI Assessment of Breast Cancer Therapy Response". The goal of this observational study is to investigate and validate multi-parametric magnetic resonance imaging (MRI) modalities for assessment of breast cancer response to neoadjuvant chemotherapy in a multi-site and multi-MRI scanner platform setting. This study is conducted at Oregon Health \& Sc...
What is the current status of trial NCT05704062?
This trial is currently recruiting. The enrollment target is 135 participants. The study started on 2010-03-18. Estimated completion is 2027-05-31.
What conditions does trial NCT05704062 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05704062?
The interventions under investigation include: Diffusion Weighted Imaging (PROCEDURE), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT05704062?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05704062 being conducted?
This trial has 4 study locations across Iowa, Michigan, Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.